Publications: MRS Katila George
Jacobs BM, Schalk L, Tregaskis-Daniels E, Scalfari A, Nandoskar A, Dunne A, Gran B, Mein CA et al.
(
2026
)
.
Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds
.
Neurology
vol.
106
,
(
7
)
Dobson R, Holden D, Vickaryous N, Bestwick J, George K, Sayali T, Bianchi L, Wafa M et al.
(
2023
)
.
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis
.
Multiple Sclerosis Journal
vol.
30
,
(
1
)
63
-
70
.
Zaloum SA, Wood CH, Tank P, Upcott M, Vickaryous N, Anderson V, Baker D, Chance R et al.
(
2023
)
.
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
.
Multiple Sclerosis Journal
vol.
29
,
(
8
)
979
-
989
.
Jacobs BM, Schalk L, Dunne A, Scalfari A, Nandoskar A, Gran B, Mein CA, Sellers C et al.
(
2023
)
.
ADAMS project: a genetic Association study in individuals from Diverse Ancestral backgrounds with Multiple Sclerosis based in the UK
.
BMJ Open
vol.
13
,
(
5
)
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Matthews PM
(
2022
)
.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
.
Journal of Neurology Neurosurgery & Psychiatry
vol.
93
,
(
9
)
Tallantyre E, Vickaryous N, Richards A, Rios F, George K, Scurr M, Loveless S
(
2022
)
.
T-cell response following COVID booster vaccination in seronegative people with multiple sclerosis
.
Journal of Neurology Neurosurgery & Psychiatry
.
vol.
93
,
Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al.
(
2022
)
.
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis
.
Multiple Sclerosis and Related Disorders
vol.
64
,
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G et al.
(
2022
)
.
Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)
.
Multiple Sclerosis and Related Disorders
vol.
63
,
Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R et al.
(
2021
)
.
COVID‐19 Vaccine Response in People with Multiple Sclerosis
.
Annals of Neurology
vol.
91
,
(
1
)
89
-
100
.
Dobson R, Holden D, Vickaryous N, Bestwick J, George K, Sayali T, Bianchi L, Wafa M et al.
.
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis
.
Tallantyre EC, Vickaryous N, Anderson V, Asardag AN, Baker D, Bestwick J, Bramhall K, Chance R et al.
.
COVID-19 vaccine response in people with multiple sclerosis
.
Jacobs BM, Schalk L, Tregaskis-Daniels E, Scalfari A, Nandoskar A, Dunne A, Gran B, Mein CA et al.
.
Genetic determinants of Multiple Sclerosis susceptibility in diverse ancestral backgrounds
.
Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al.
.
Response to COVID-19 booster vaccinations in seronegative people with MS
.